chloro(phenyl)methyl carbonochloridate | 81363-09-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: chloro(phenyl)methyl carbonochloridate
• 英文别名: α-chlorobenzyl chloroformate；alpha-Chlorobenzyl chloroformate；[chloro(phenyl)methyl] carbonochloridate
• CAS: 81363-09-9
• 化学式: C₈H₆Cl₂O₂
• 分子量: 205.04
• InChiKey: XRKNLWJGODKLMG-UHFFFAOYSA-N

物化性质

• 沸点：
  78-80 °C(Press: 2 Torr)
• 密度：
  1.373±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  chloro(phenyl)methyl carbonochloridate 在 samarium diiodide 作用下， 以 四氢呋喃 为溶剂， 反应 0.08h， 以90%的产率得到反式-1,2-二苯乙烯
  参考文献：
  名称：

  Li, Zhifang; Zhang, Yongmin, Journal of Chemical Research - Part S, 2003, # 6, p. 340 - 341

  摘要：

  DOI：
• 作为产物：
  描述：

  三光气 、 苯甲醛 在 吡啶 作用下， 以 四氯化碳 为溶剂， 以82%的产率得到chloro(phenyl)methyl carbonochloridate
  参考文献：
  名称：

  碳酸三氯甲基酯作为实用的光气来源：在合成α-氯代氯甲酸酯中的应用

  摘要：

  碳酸三氯甲基酯1在制备α-氯代氯甲酸酯中用作光气源。这种稳定的结晶试剂可在温和条件下平稳地以高收率顺利交付产品3。

  DOI：

  10.1016/s0040-4039(01)93704-9

文献信息

• Cyanoguanidine prodrugs
  申请人：——

  公开号：US20020165201A1

  公开（公告）日：2002-11-07

  The invention relates to compounds of the formula I 1 wherein X 1 and X 2 independently represent a bond; a straight, branched and/or cyclic hydrocarbon diradical, optionally substituted with one or more hydroxy, halogen, nitro, amino, cyano, aminosulfonyl, alkylsulfonylamino, alkylcarbonyl, formyl, aminocarbonyl or alkylcarbonylamino; a heteroarylene or non-aromatic heterocyclic hydrocarbon diradical, all of which are optionally substituted with one or more straight, branched and/or cyclic non-aromatic hydrocarbon radical, hydroxyl, halogen, amino, nitro, cyano, aminosulfonyl, alkylsulfonylamino, alkylcarbonyl, formyl, aminocarbonyl or alkylcarbonylamino; Y 1 and Y 2 independently represent a bond, an ether diradical (R′—O—R″), an amine diradical (R′—N—R″), O, S, S(O), S(O) 2 , C(O), NH—CO, CO—NH, SO 2 —N(R′), methylene or N(R′)—SO 2 wherein R′ and R″ independently represent straight or branched hydrocarbon diradicals containing up to 4 carbon atoms; Y 3 represents O, O—C(O), C(O)—O, N(R 8 ), R 8 being hydrogen or C 1-4 alkyl R 1 represents hydrogen or straight, branched and/or cyclic alkyl, optionally substituted with phenyl; or an aromatic hydrocarbon radical; R 2 represents aryl, heteroaryl or a non-aromatic heterocyclic hydrocarbon radical, all of which are optionally substituted; tetrahydropyranyloxy, di-(C 1-4 alkoxy)phosphinoyloxy or C 1-4 alkoxycarbonylamino; R 3 represents hydrogen; a straight, branched and/or cyclic hydrocarbon radical, optionally substituted with one or more amino, hydroxy, carboxy, halogen, nitro, cyano, alkoxy, aminocarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkoxycarbonylamino, sulfo, hydroxysulfonyloxy, dihydroxyphosphinoyloxy, phosphono, sulfamino, aminosulfonyl, aminoacylamino or dialkoxyphosphinoyl; heteroaryl or a non-aromatic heterocyclic hydrocarbon radical, all of which are optionally substituted with one or more straight, branched and/or cyclic hydrocarbon radical, amino, hydroxy, carboxy, halogen, nitro, cyano, alkoxy, aminocarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkoxycarbonylamino, sulfo, hydroxysulfonyloxy, dihydroxyphosphinoyloxy, phosphono, sulfamino, aminosulfonyl, aminoacylamino or dialkoxyphosphinoyl; 2 wherein s is an integer from 1 to 200; R 6 is hydrogen or an optionally substituted non-aromatic hydrocarbon radical; R 7 is independently hydrogen or methyl; R 4 and R 5 independently represent hydrogen; a straight, branched and/or cyclic hydrocarbon radical, optionally substituted with halogen, hydroxyl, halogen, amino, nitro or cyano; A represents hydrogen, an optionally substituted, straight, branched and/or cyclic hydrocarbon radical, hydroxy, halogen, nitro, cyano, heteroaryl, heteroaralkyl or thiol; m and r are independently integers from 0 to 4; and n is 0 or 1; Z − is a pharmaceutically acceptable anion, such as chloride, bromide, iodide, sulfate, methanesulfonate, p-toluenesulfonate, nitrate or phosphate. The compounds are well suited as prodrugs in human and veterinary therapy.

  该发明涉及以下式I的化合物： 其中X1和X2分别表示键；一种直链、支链和/或环烃二自由基，可选择地取代一个或多个羟基、卤素、硝基、氨基、氰基、氨基磺酰基、烷基磺酰胺基、烷基羰基、甲酰基、氨基羰基或烷基羰基氨基；一种杂芳烃基或非芳香杂环烃二自由基，均可选择地取代一个或多个直链、支链和/或环非芳香烃基、羟基、卤素、氨基、硝基、氰基、氨基磺酰基、烷基磺酰胺基、烷基羰基、甲酰基、氨基羰基或烷基羰基氨基； Y1和Y2分别表示键、醚二自由基（R′—O—R″）、胺二自由基（R′—N—R″）、O、S、S(O)、S(O)2、C(O)、NH—CO、CO—NH、SO2—N(R′)、亚甲基或N(R′)—SO2，其中R′和R″分别表示含有最多4个碳原子的直链或支链烃基； Y3表示O、O—C(O)、C(O)—O、N(R8)，其中R8为氢或C1-4烷基 R1表示氢或直链、支链和/或环烷基，可选择地取代苯基；或芳香烃基； R2表示芳基、杂芳基或非芳香杂环烃基，均可选择地取代；四氢吡喃氧基、二-(C1-4烷氧)磷酰氧基或C1-4烷氧羰基氨基； R3表示氢；一种直链、支链和/或环烃基，可选择地取代一个或多个氨基、羟基、羧基、卤素、硝基、氰基、烷氧基、氨基羰基、C1-4烷氧羰基、C1-4烷氧羰基氨基、磺酰基、羟基磺酰氧基、二羟基磷酰氧基、磷酸酯、磺胺基、氨基磺酰基、氨基酰氨基或二烷氧基磷酰基；杂芳基或非芳香杂环烃基，均可选择地取代一个或多个直链、支链和/或环烃基、氨基、羟基、羧基、卤素、硝基、氰基、烷氧基、氨基羰基、C1-4烷氧羰基、C1-4烷氧羰基氨基、磺酰基、羟基磺酰氧基、二羟基磷酰氧基、磷酸酯、磺胺基、氨基磺酰基、氨基酰氨基或二烷氧基磷酰基； 其中s为1至200的整数；R6为氢或可选择地取代的非芳香烃基；R7独立地为氢或甲基； R4和R5独立地表示氢；一种直链、支链和/或环烃基，可选择地取代卤素、羟基、卤素、氨基、硝基或氰基； A表示氢、可选择地取代的直链、支链和/或环烃基、羟基、卤素、硝基、氰基、杂芳基、杂芳基烷基或硫醇；m和r独立地为0至4的整数；n为0或1； Z-为药用可接受的阴离子，如氯化物、溴化物、碘化物、硫酸盐、甲磺酸盐、对甲苯磺酸盐、硝酸盐或磷酸盐。这些化合物非常适用于人类和兽医治疗中作为前药。
• PRODRUGS OF NH-ACIDIC COMPOUNDS: ESTER, CARBONATE, CARBAMATE AND PHOSPHONATE DERIVATIVES
  申请人：Blumberg Laura Cook

  公开号：US20110319422A1

  公开（公告）日：2011-12-29

  The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

  该发明提供了一种持续释放内酰胺、亚酰胺、酰胺、磺胺、碳酸酯或尿素含有母药的方法，通过向患者施用该发明的一种前药化合物的有效量，在向患者施用后，从前药中释放母药是持续释放的。适用于该发明方法的前药化合物是母药的不稳定结合物，通过羰基连接的前药基团进行衍生化。该发明的前药化合物可用于治疗任何需要内酰胺、亚酰胺、酰胺、磺胺、碳酸酯或尿素含有母药作为治疗的情况。
• Benzaldehyde-derived chloroformates and their application towards the synthesis of methoxyfenozide- N -[(acyloxy)benzyloxy]carbonyl derivatives
  作者：Mark J Mulvihill、Duyan V Nguyen、Brian MacDougall、Blanca Martinez-Teipel、Rhoda Joseph、James Gallagher、Damian Weaver、Arkady Gusev、KiHo Chung、William Mathis

  DOI：10.1016/s0040-4039(01)01644-6

  日期：2001.10

  The synthesis of a series of substituted benzaldehyde-derived chloroformates and their application towards the synthesis of a diverse series of novel insecticidally active carboxylic acid [N′-tert-butyl-N′-(3,5-dimethylbenzoyl)-N-(3-methoxy-2-methylbenzoyl)hydrazinocarbonyloxy]phenylmethyl esters, prepared in a parallel synthesis fashion, is reported.

  一系列取代的苯甲醛衍生的氯甲酸酯的合成和它们向一个多样化一系列新颖杀虫活性羧酸[合成应用Ñ ' -叔丁基- ñ ' - （3,5-二甲基苯甲酰） - ñ - （3-报道了以平行合成方式制备的-甲氧基-2-甲基苯甲酰基）肼基羰氧基]苯基甲基酯。
• Process for the preparation of .alpha.-chlorinated chloroformates
  申请人：Societe Nationale des Poudres et Explosifs

  公开号：US04614829A1

  公开（公告）日：1986-09-30

  Process for the preparation of .alpha.-chlorinated chloroformates with the formula ##STR1## where R is H, an aliphatic or aromatic hydrocarbon radical or heterocyclic radical, substituted or non-substituted and n an integer. The process consists of reacting ClCOOCCl.sub.3 or Cl.sub.3 COCOOCCl.sub.3 with an aldehyde with formula R--(CHO).sub.n in the presence of a compound, which in the medium releases a pair of ions, the anion of which being a halide which can attack the aldehyde function, because of the weak attractive power of the cation of this compound.

  制备.alpha.-氯代氯甲酸酯的过程，其化学式为##STR1## 其中R为H，脂肪或芳香族烃基或取代或未取代的杂环基，n为整数。该过程包括在存在一种化合物的情况下，该化合物在介质中释放出一对离子，其中阴离子是一种卤化物，可以攻击醛功能基，因为该化合物的阳离子具有较弱的吸引力，通过将ClCOOCCl.sub.3或Cl.sub.3 COCOOCCl.sub.3与化学式为R--(CHO).sub.n的醛反应。
• Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
  申请人：Blumberg Laura Cook

  公开号：US08592427B2

  公开（公告）日：2013-11-26

  The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

  本发明提供了一种持续释放内酰胺、亚酰胺、酰胺、磺酰胺、氨基甲酸酯或尿素含量原药的方法，通过向患者施用本发明的前药化合物的有效量，在患者体内，从前药中释放出原药的持续释放。适用于本发明方法的前药化合物是通过羰基连接的前药基团衍生化的，是前药原药的不稳定结合物。本发明的前药化合物可用于治疗任何需要使用内酰胺、亚酰胺、酰胺、磺酰胺、氨基甲酸酯或尿素含量原药作为治疗的情况。